Collectionner le produit
Détails du produit
Source
Chimeric Monoclonal Anti-BCMA Antibody, Mouse IgG1 (AM43) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to mouse IgG1 constant domains.
Antibody Type
Recombinant Monoclonal
Clone
AM43
Isotype
Mouse IgG1, Kappa
Host Species
Mouse
Reactivity
Human
Immunogen
BCMA
Specificity
The product specifically targets the extracellular domain of human BCMA protein and inhibits the interaction between BCMA and BAFF (IC50 = 14.79 μg/mL), as well as BCMA and APRIL (IC50 = 17.03 μg/mL).
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLCross Verification
Positive: Cross-reactive by ELISA with human, cynomolgus and mouse BCMA protein.
Purification
Protein A purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in Tris (pH 7.5) containing 100 mM Glycine, 25 mM Arginine and 150 mM NaCl, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-ELISA
Immobilized Human BCMA Protein, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-BCMA Antibody, Mouse IgG1 (AM43) (Cat. No. BCA-M43) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Monoclonal Anti-BCMA Antibody, Mouse IgG1 (AM43) (Clone: AM43, Cat. No. BCA-M43) and 0.05 μg/mL (100 μL/well) Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a half maximal inhibitory concentration (IC50) of 17.03 μg/mL (Routinely tested).
Protocol
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Monoclonal Anti-BCMA Antibody, Mouse IgG1 (AM43) (Clone: AM43, Cat. No. BCA-M43) and 0.01 μg/mL (100 μL/well) Biotinylated Human BAFF, His,Avitag (Cat. No. BAF-H82Q2) with a half maximal inhibitory concentration (IC50) of 14.79 μg/mL (Routinely tested).
Protocol
Bioactivity-SPR
Monoclonal Anti-BCMA Antibody, Mouse IgG1 (AM43) (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
B-cell maturation protein
- Catégorie：
- Nombre de médicaments répertoriés：
8 Détails
- Nombre de médicaments cliniques：
145 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
